A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

NCT04943068 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoactive Sexual Desire Disorder

Interventions

DRUG: Bremelanotide
DRUG: Placebo

Sponsor

Kwang Dong Pharmaceutical co., ltd.